CLAIMS

1. **Use of benzyl ester of** hyaluronic acid or **a cross-linked derivative of hyaluronic acid wherein the carboxy groups of hyaluronic acid are cross-linked to the hydroxyl group of the same or different hyaluronic acid molecule,** for the preparation of a **biomaterial** suitable for antiangiogenic therapy to treat primary and secondary tumours.

2. **The use according to claim 1** wherein hyaluronic acid is in association with other natural, synthetic and/or semisynthetic biopolymers.

3. The use according to claim 2, wherein the natural biopolymer is selected from the group consisting of collagen, cellulose, polysaccharides, chitin, chitosan, pectins, agar, gellan and alginic acid.

4. The use according to claim 2, wherein the synthetic biopolymer is selected from the group consisting of polylactic acid (PLA), polyglycolic acid (PGA), polyurethanes and polysulphonic resins.

5. The use according to claim 2, wherein the semisynthetic biopolymer is selected from the group consisting of collagen cross-linked with aldehydes, diamine and gellan.

6. The use according to claim 1 wherein the biomaterial is associated with pharmacologically active substances.

7. The use according to claim 6, wherein the pharmacologically active substance **is selected from the group consisting of** fluorouracil, methotrexate, cis-platinum, carboplatin, oxaliplatin, ethopoxide, cyclophosphamide, vincristine, doxorubicin.

8. The use according to any one of claims 1-7 wherein the biomaterial is in the form of a non-woven felt, sponge, microsphere, film or membrane and/or other three-dimensional structures.

9. The use according to any one of claims 1-8, for the treatment and care of primary and secondary tumours when the tumour has been surgically removed and the cavity that is thus formed requires filling.